VIII. Net Income to Adjusted EBITDA and Earnings per Common Share to Adjusted Earnings per Common Share ReconciliationsBusiness Outlook for the Year Ending December 31, 2019(In millions, unaudited) | |||||||
The following are reconciliations of full year 2019 Adjusted EBITDA and adjusted earnings per common share expectations as computed at the low and high points of the range to the closest comparable GAAP financial measure. Refer to table VI and table VII for a discussion of Select Medical's use of Adjusted EBITDA and adjusted earnings per common share in evaluating financial performance. Refer to table VI for the definition of Adjusted EBITDA. Each item presented in the below tables are estimations of full year 2019 expectations. | |||||||
Range | |||||||
Non-GAAP Measure Reconciliation | Low | High | |||||
Net income attributable to Select Medical | $ | 137 | $ | 158 | |||
Net income attributable to non-controlling interests | 56 | 65 | |||||
Net income | 193 | 223 | |||||
Income tax expense | 66 | 76 | |||||
Interest expense | 200 | 200 | |||||
Equity in earnings of unconsolidated subsidiaries | (25) | (25) | |||||
Non-operating gain | (7) | (7) | |||||
Income from operations | 427 | 467 | |||||
Stock compensation expense | 27 | 27 | |||||
Depreciation and amortization | 206 | 206 | |||||
Adjusted EBITDA | $ | 660 | $ | 700 | |||
Range | |||||||
Non-GAAP Measure Reconciliation | Low | High | |||||
Diluted earnings per common share | $ | 1.00 | $ | 1.16 | |||
Adjustments: | |||||||
Non-operating gain | (0.03) | (0.03) | |||||
Adjusted earnings per common share | $ | 0.97 | $ | 1.13 | |||
